A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complement

Virology Journal

Volumn 7, Issue , 2010, Pages

  Jia, Leili ^a   Xu, Yuanyong ^a   Zhang, Chuanfu ^a   Wang, Yong ^a   Chong, Huihui ^b   Qiu, Shaofu ^a   Wang, Ligui ^a   Zhong, Yanwei ^d   Liu, Weijing ^a   Sun, Yansong ^a   Qiao, Fei ^c   Tomlinson, Stephen ^c   Song, Hongbin ^a   Zhou, Yusen ^a   He, Yuxian ^b  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b INSTITUTE OF PATHOGEN BIOLOGY   (China)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d BEIJING 302 HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT RECEPTOR; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G1 ANTIBODY; ANTIBODY; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G;

CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; LYSIS; PROTEIN EXPRESSION; REVIEW; VIRION; VIRUS ACTIVATION; VIRUS CULTURE; VIRUS NEUTRALIZATION; ARTICLE; CELL LINE; COMPLEMENT ACTIVATION; DOWN REGULATION; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODIES; CELL LINE; COMPLEMENT ACTIVATION; COMPLEMENT C3; DOWN-REGULATION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G;

EID: 77953955363     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-142     Document Type: Review

References (25)

1. Coming to terms with complexity: a call to action for HIV prevention. P Piot M Bartos H Larson D Zewdie P Mane, Lancet 2008 372 845 859 10.1016/S0140-6736(08)60888-0 18687458
2. Protection from HIV/AIDS: the importance of innate immunity. JA Levy I Scott C Mackewicz, Clin Immunol 2003 108 167 174 10.1016/S1521-6616(03)00178-5 14499239
3. HIV and complement: hijacking an immune defense. PK Datta J Rappaport, Biomed Pharmacother 2006 60 561 568 10.1016/j.biopha.2006.07.087 16978830
4. Complement-HIV interactions during all steps of viral pathogenesis. H Stoiber Z Banki D Wilflingseder MP Dierich, Vaccine 2008 26 3046 3054 10.1016/j.vaccine.2007.12.003 18191309
5. Complement. First of two parts. MJ Walport, N Engl J Med 2001 344 1140 1144 10.1056/NEJM200104123441506 11297706
6. Complement-opsonized HIV: the free rider on its way to infection. H Stoiber M Pruenster CG Ammann MP Dierich, Mol Immunol 2005 42 153 160 10.1016/j.molimm.2004.06.024 15488605
7. HIV and human complement: inefficient virolysis and effective adherence. Z Banki H Stoiber MP Dierich, Immunol Lett 2005 97 209 214 10.1016/j.imlet.2004. 11.007 15752560
8. C-type lectin-independent interaction of complement opsonized HIV with monocyte-derived dendritic cells. M Pruenster D Wilflingseder Z Banki CG Ammann B Muellauer M Meyer C Speth MP Dierich H Stoiber, Eur J Immunol 2005 35 2691 2698 10.1002/eji.200425940 16094691
9. A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils. M Duval MR Posner LA Cavacini, J Virol 2008 82 4671 4674 10.1128/JVI.02499-07 18272577
10. A novel approach to inhibit HIV-1 infection and enhance lysis of HIV by a targeted activator of complement. Y Xu C Zhang L Jia C Wen H Liu Y Wang Y Sun L Huang Y Zhou H Song, Virol J 2009 6 123 10.1186/1743-422X-6-123 19671191
11. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction. M Saifuddin T Hedayati JP Atkinson MH Holguin CJ Parker GT Spear, J Gen Virol 1997 78 Pt 8 1907 1911 9266986
12. Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1. H Stoiber R Schneider J Janatova MP Dierich, Immunobiology 1995 193 98 113 7590866
13. Role of complement in HIV infection. H Stoiber A Clivio MP Dierich, Annu Rev Immunol 1997 15 649 674 10.1146/annurev.immunol.15.1.649 9143703
14. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo. BL Sullivan EJ Knopoff M Saifuddin DM Takefman MN Saarloos BE Sha GT Spear, J Immunol 1996 157 1791 1798 8759769
15. A "complement-ary" AIDS vaccine. MP Dierich H Stoiber A Clivio, Nat Med 1996 2 153 155 10.1038/nm0296-153 8574953
16. Acquisition of host cell-surface-derived molecules by HIV-1. I Frank H Stoiber S Godar H Stockinger F Steindl HW Katinger MP Dierich, AIDS 1996 10 1611 1620 8970680
17. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. M Saifuddin CJ Parker ME Peeples MK Gorny S Zolla-Pazner M Ghassemi IA Rooney JP Atkinson GT Spear, J Exp Med 1995 182 501 509 10.1084/jem.182.2.501 7543140
18. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. J Schmitz JP Zimmer B Kluxen S Aries M Bogel I Gigli H Schmitz, J Clin Invest 1995 96 1520 1526 10.1172/JCI118190 7544808
19. Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis. DM Takefman BL Sullivan BE Sha GT Spear, Virology 1998 246 370 378 10.1006/viro.1998.9205 9657955
20. Cutting edge: productive HIV-1 infection of dendritic cells via complement receptor type 3 (CR3, CD11b/CD18). Z Bajtay C Speth A Erdei MP Dierich, J Immunol 2004 173 4775 4778 15470016
21. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). H Stoiber C Pinter AG Siccardi A Clivio MP Dierich, J Exp Med 1996 183 307 310 10.1084/jem.183.1.307 8551237
22. Enhancement of complement-mediated lysis by a peptide derived from SCR 13 of complement factor H. H Stoiber C Ammann M Spruth B Mullauer A Eberhart CL Harris CG Huber R Longhi B Falkensammer R Wurzner MP Dierich, Immunobiology 2001 203 670 686 11402501
23. A revival of bispecific antibodies. P Kufer R Lutterbuse PA Baeuerle, Trends Biotechnol 2004 22 238 244 10.1016/j.tibtech.2004.03.006 15109810
24. Fc receptor but not complement binding is important in antibody protection against HIV. AJ Hessell L Hangartner M Hunter CE Havenith FJ Beurskens JM Bakker CM Lanigan G Landucci DN Forthal PW Parren PA Marx DR Burton, Nature 2007 449 101 104 10.1038/nature06106 17805298
25. Humoral immunity to HIV-1: neutralisation and antibody effector functions. S Willey MM Aasa-Chapman, Trends Microbiol 2008 16 596 604 10.1016/j.tim.2008.08.008 18964020